SOURCE: The Bedford Report

The Bedford Report

June 30, 2011 08:16 ET

Pain Therapeutics and Neoprobe Present Promising Pipelines

The Bedford Report Provides Stock Research on Pain Therapeutics & Neoprobe Corporation

NEW YORK, NY--(Marketwire - Jun 30, 2011) - There is plenty of optimism surrounding the biotech sector as firmer pricing and new products have improved sales and earnings trends. Meanwhile, younger, more speculative firms continue to garner significant attention with potential blockbuster products working their way through the regulatory process. The Bedford Report examines the outlook for companies in the biotechnology industry and provides equity research on Pain Therapeutics, Inc. (NASDAQ: PTIE) and Neoprobe Corporation (NASDAQ: NEOP). Access to the full company reports can be found at:

www.bedfordreport.com/PTIE

www.bedfordreport.com/NEOP

The importance of maintaining a steady pipeline of drugs to market is having varied effects on the biotechnology industry. Larger firms are leaning on acquisitions to quickly expand their product lines while smaller ones are opting for increased spending on research and development. This creates two potential avenues of profit for speculative biotech investors: a greater chance of a blockbuster drug or being acquired by a larger firm eager to boost its pipeline.

The Bedford Report releases investment research on the Biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

Pain Therapeutics presently has four candidates in clinical programs. Earlier this week the company said that the US Food and Drugs Administration pointed out inconsistency issues related to in vitro testing of the investigational painkiller "remoxy" while rejecting the new drug application. Remoxy has been considered a possible competitor to OxyContin, which had annual sales of about $3 billion before generic forms of the drug came to market.

Neoprobe is a biomedical company focused on enhancing oncology patient care and improving patient benefit. Neoprobe currently markets the neoprobe GDS line of gamma detection systems that are widely used by cancer surgeons.

The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer

Contact Information